CreatorsPublishersAdvertisers
View more in
Diseases & Treatments

Dr. Ailawadhi on Patient Considerations for BTK Inhibitors in Waldenström Macroglobulinemia

onclive.com
 2021-09-03

Sikander Ailawadhi, MD, discusses patient considerations for BTK inhibitors in Waldenström macroglobulinemia. Sikander Ailawadhi, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic, discusses patient considerations for BTK inhibitors in Waldenström macroglobulinemia. The availability and cost...

www.onclive.com

Comments / 0

Comments / 0